Clinical trial
Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer
NCT00006230 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00006230 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer |
| Official title | Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced Ovarian Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Enrollment | 51 |
| Start date | May 1, 2000 |
| Primary completion | Apr 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 24, 2012 |
| Countries | Belgium, France, Israel, Italy, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: